UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2010, Volume 55, Issue 18, pp. 1915 - 1922
Treprostinil sodium | Inhalation therapy | Aerosol | Pulmonary heart disease | Pulmonary vascular disease | Prostacyclin | Pulmonary arterial hypertension | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Piperazines - administration & dosage | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Purines - administration & dosage | Exercise Tolerance - drug effects | Sildenafil Citrate | Young Adult | Peptide Fragments - blood | Adult | Female | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Natriuretic Peptide, Brain - blood | Administration, Oral | Administration, Inhalation | Treatment Outcome | Epoprostenol - analogs & derivatives | Quality of Life | Aged | Vasodilator Agents - administration & dosage | Sulfonamides - administration & dosage | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Hypertension | Studies | Pulmonary arteries | Collagen | Family medical history | Drug therapy | Drug dosages
Journal Article
Annals of internal medicine, ISSN 0003-4819, 10/2008, Volume 149, Issue 8, pp. 521 - 530
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases | Medical sciences | Pneumology | Piperazines - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Sulfones - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Dyspepsia - chemically induced | Purines - administration & dosage | Hemodynamics - physiology | Walking - physiology | Sildenafil Citrate | Time Factors | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Purines - adverse effects | Drug Therapy, Combination | Headache - chemically induced | Double-Blind Method | Administration, Oral | Piperazines - adverse effects | Antihypertensive Agents - adverse effects | Adolescent | Quality of Life | Aged | Vasodilator Agents - adverse effects | Hypertension, Pulmonary - etiology | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Complications and side effects | Epoprostenol | Dosage and administration | Sildenafil | Drug therapy, Combination | Research | Drug therapy | Pulmonary hypertension | Hypertension | Inhibitor drugs | Patients | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of pharmacology and experimental therapeutics, ISSN 0022-3565, 12/2017, Volume 363, Issue 3, pp. 348 - 357
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Antihypertensive Agents - pharmacology | Nanoparticles - chemistry | Vasodilator Agents - pharmacokinetics | Phosphatidylethanolamines - adverse effects | Humans | Excipients - adverse effects | Male | Polyethylene Glycols - chemistry | Squalene - analogs & derivatives | Drug Compounding | Hypertension, Pulmonary - drug therapy | Epoprostenol - pharmacokinetics | Guinea Pigs | Squalene - adverse effects | Antihypertensive Agents - therapeutic use | Excipients - administration & dosage | Rats, Sprague-Dawley | Epoprostenol - analogs & derivatives | Lung - drug effects | Vasodilation - drug effects | Phosphatidylethanolamines - chemistry | Drug Delivery Systems - adverse effects | Epoprostenol - administration & dosage | Prodrugs - administration & dosage | Epoprostenol - metabolism | Vasodilator Agents - therapeutic use | Antihypertensive Agents - administration & dosage | Polyethylene Glycols - adverse effects | Hypertension, Pulmonary - blood | Nanoparticles - adverse effects | Dose-Response Relationship, Drug | Epoprostenol - therapeutic use | Excipients - chemistry | Epoprostenol - pharmacology | Female | Lung - metabolism | Platelet Aggregation - drug effects | Drug Evaluation, Preclinical | Squalene - chemistry | Vasodilator Agents - pharmacology | Administration, Inhalation | Phosphatidylethanolamines - administration & dosage | Squalene - administration & dosage | Antihypertensive Agents - pharmacokinetics | Polyethylene Glycols - administration & dosage | Animals | Prodrugs - pharmacokinetics | Dogs | Nanoparticles - administration & dosage | Prodrugs - therapeutic use | Lung - blood supply | Prodrugs - pharmacology | Vasodilator Agents - administration & dosage | Index Medicus
Journal Article
Chest, ISSN 0012-3692, 2013, Volume 144, Issue 3, pp. 952 - 958
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Exercise Tolerance - drug effects | Dose-Response Relationship, Drug | Young Adult | Time Factors | Adult | Female | Blood Pressure - drug effects | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Endothelin Receptor Antagonists | Double-Blind Method | Administration, Oral | Phosphodiesterase 5 Inhibitors - administration & dosage | Familial Primary Pulmonary Hypertension | Treatment Outcome | Epoprostenol - analogs & derivatives | Adolescent | Aged | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Complications and side effects | Care and treatment | Patient outcomes | Treprostinil | Clinical trials | Dosage and administration | Research | Drug therapy | Pulmonary hypertension | Index Medicus | Abridged Index Medicus
Journal Article
Chest, ISSN 0012-3692, 06/2020, Volume 157, Issue 6, pp. A41 - A41
Journal Article
Pharmacological research, ISSN 1043-6618, 12/2016, Volume 114, pp. 103 - 109
Female | Male | Pulmonary arterial hypertension | Treatment | Gender | Risk stratification | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Endothelin Receptor Antagonists - administration & dosage | Humans | Phosphodiesterase 5 Inhibitors - administration & dosage | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Treatment Outcome | Hypertension, Pulmonary - epidemiology | Antihypertensive Agents - therapeutic use | Epoprostenol - therapeutic use | Epoprostenol - analogs & derivatives | Sex Factors | Hypertension, Pulmonary - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Endothelin Receptor Antagonists - therapeutic use | Epoprostenol - administration & dosage | Drug therapy | Cardiology | Pulmonary hypertension | Index Medicus
Journal Article
The European respiratory journal, ISSN 0903-1936, 1791, Volume 43, Issue 6, pp. 1691 - 1697
Life Sciences & Biomedicine | Respiratory System | Science & Technology | Piperazines - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Treatment Outcome | Purines - administration & dosage | Sildenafil Citrate | Young Adult | Drug Therapy, Combination - methods | Pilot Projects | Adolescent | Adult | Female | Registries | Aged | Hypertension, Pulmonary - drug therapy | Retrospective Studies | Sulfonamides - administration & dosage | Epoprostenol - administration & dosage | Sulfones - administration & dosage
Journal Article
Chest, ISSN 0012-3692, 06/2009, Volume 135, Issue 6, pp. 1455 - 1461
Prostacyclin | Bosentan | Sildenafil | Sarcoidosis | Pulmonary hypertension | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Cardiology. Vascular system | Biological and medical sciences | Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases | Medical sciences | Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis | Pneumology | Piperazines - administration & dosage | Sarcoidosis - mortality | Follow-Up Studies | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Purines - administration & dosage | Hemodynamics - physiology | Sildenafil Citrate | Statistics, Nonparametric | Female | Hypertension, Pulmonary - drug therapy | Retrospective Studies | Drug Therapy, Combination | Severity of Illness Index | Hypertension, Pulmonary - mortality | Sarcoidosis - diagnosis | Iloprost - administration & dosage | Risk Assessment | Administration, Oral | Kaplan-Meier Estimate | Administration, Inhalation | Probability | Linear Models | Survival Rate | Treatment Outcome | Sarcoidosis - complications | Aged | Hemodynamics - drug effects | Respiratory Function Tests | Hypertension, Pulmonary - etiology | Sulfonamides - administration & dosage | Cohort Studies | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Index Medicus | Abridged Index Medicus | sarcoidosis | Original Research | bosentan | prostacyclin | sildenafil | pulmonary hypertension
Journal Article
9.
Full Text
A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration
Clinical pharmacokinetics, ISSN 0312-5963, 12/2016, Volume 55, Issue 12, pp. 1495 - 1505
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Drug Administration Routes | Epoprostenol - pharmacokinetics | Area Under Curve | Antihypertensive Agents - administration & dosage | Metabolic Clearance Rate | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - therapeutic use | Circadian Rhythm | Dose-Response Relationship, Drug | Epoprostenol - therapeutic use | Epoprostenol - analogs & derivatives | Maximum Tolerated Dose | Drug Interactions | Hypertension, Pulmonary - drug therapy | Delayed-Action Preparations | Epoprostenol - administration & dosage
Journal Article
Respiratory care, ISSN 0020-1324, 06/2015, Volume 60, Issue 6, pp. 794 - 802
Aerosol therapies | Pulmonary arterial hypertension | Inhaled nitric oxide | Inhaled route | Pulmonary hypertension | Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Off-Label Use | Iloprost - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Administration, Inhalation | Antihypertensive Agents - administration & dosage | Nitric Oxide - administration & dosage | Prostaglandins I - administration & dosage | Epoprostenol - analogs & derivatives | Adult | Hypertension, Pulmonary - drug therapy | Vasodilator Agents - administration & dosage | Infant, Newborn | Epoprostenol - administration & dosage | Cell proliferation | Usage | Care and treatment | Nitric oxide | Analysis | Diagnosis | Health aspects | Pressure | Index Medicus
Journal Article
Journal of controlled release, ISSN 0168-3659, 01/2015, Volume 197, pp. 97 - 104
Encapsulation | Biodegradable nanoparticle | Pulmonary arterial hypertension | Beraprost sodium | Prostaglandin I | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Polymers - administration & dosage | Rhodamines - administration & dosage | Nanoparticles - chemistry | Rats, Wistar | Monocrotaline | Capillary Permeability - drug effects | Drug Carriers - administration & dosage | Delayed-Action Preparations - chemistry | Male | Polyethylene Glycols - chemistry | Drug Carriers - chemistry | Delayed-Action Preparations - administration & dosage | Pulmonary Artery - metabolism | Delayed-Action Preparations - pharmacokinetics | Polyesters | Hypertension, Pulmonary - drug therapy | Rhodamines - chemistry | Lactic Acid - administration & dosage | Disease Models, Animal | Epoprostenol - pharmacokinetics | Lactic Acid - chemistry | Mice, Inbred C57BL | Hypertension, Pulmonary - metabolism | Pulmonary Artery - drug effects | Polyethylene Glycols - administration & dosage | Epoprostenol - analogs & derivatives | Animals | Epoprostenol - chemistry | Polymers - chemistry | Drug Carriers - pharmacokinetics | Nanoparticles - administration & dosage | Hypertension, Pulmonary - pathology | Pulmonary Artery - pathology | Epoprostenol - administration & dosage | Nanoparticles | Fluorescence | Models | Analysis | Pulmonary hypertension | Drugs | Drug delivery systems | Drug discovery | Vehicles | Index Medicus
Journal Article
Journal of cardiovascular pharmacology, ISSN 0160-2446, 04/2016, Volume 67, Issue 4, pp. 290 - 298
Prostacyclin | Pulmonary arterial smooth muscle cells | Drug delivery system | Nanomedicine | Pulmonary hypertension | Intratracheal administration | Cardiac & Cardiovascular Systems | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Humans | Male | Hypertension, Pulmonary - prevention & control | Drug Delivery Systems | Hypertrophy, Right Ventricular - drug therapy | Cell Hypoxia | Nanoparticles | Young Adult | Pulmonary Artery - metabolism | Time Factors | Adult | Epoprostenol - pharmacology | Female | Hypertrophy, Right Ventricular - pathology | Myocytes, Smooth Muscle - drug effects | Child | Myocytes, Smooth Muscle - metabolism | Disease Models, Animal | Rats | Monocrotaline - toxicity | Pulmonary Artery - drug effects | Rats, Sprague-Dawley | Epoprostenol - analogs & derivatives | Animals | Adolescent | Cell Proliferation - drug effects | Epoprostenol - administration & dosage | Index Medicus | intratracheal administration | prostacyclin | pulmonary hypertension | pulmonary arterial smooth muscle cells | nanomedicine | drug delivery system | Original
Journal Article